TABLE 2.

Summary of Tumor Radiation Dose Estimations

Patient	[¹⁷⁷Lu]Lu-DOTATOC, 1 cycle^*				[¹⁷⁷Lu]Lu-DOTA-JR11, 1 cycle^†				2–3 cycles^†
Patient	Meningioma dose (Gy/cycle)	Red marrow dose (Gy/cycle)	T/BM	T/K	Meningioma dose (Gy/cycle)	Red marrow dose (Gy/cycle)	T/BM ratio	T/K ratio	Meningioma dose (Gy)
1	0.8	0.05	16	0.6	4.7	0.16	30	3.0	9.5
2	1.9	0.10	19	0.6	8.4	0.31	27	1.8	15.3
3	4.4	0.15	28	1.5	14.5	0.27	54	4.6	32.3
4	5.0	0.17	30	0.9	15.0	0.39	38	2.5	43.4
5	10.2	0.13	78	4.0	22.7	0.34	66	8.1	57.7
6	2.5	0.08	29	1.0	7.1	0.24	30	2.0	13.5
Median	3.4	0.11	29	1.0	11.5	0.29	34	2.8	23.8
Range	0.8–10.2	0.05–0.17	16–78	0.6–4.0	4.7–22.7	0.16–0.39	25–66	1.8–8.1	9.5–57.7

↵* First therapy cycle was performed with 7.4 GBq ± 10% [¹⁷⁷Lu]Lu-DOTATOC.
↵† All [¹⁷⁷Lu]Lu-DOTA-JR11 therapy cycles were conducted with 2 GBq × body surface area ± 10% per cycle.
T/BM = tumor-to-red bone marrow ratio; T/K = tumor-to-kidney ratio.